NL-OMON23571
Recruiting
Not Applicable
Muticentre study to investigate the efficacy of scalp cooling for the prevention of Myocet/cyclofosfamideinducedalopecia in patients with metastatic breast cancer. MyCap study.
Stichting DIADOC0 sites70 target enrollmentTBD
Conditionschemotherapy-induced alopecia
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- chemotherapy-induced alopecia
- Sponsor
- Stichting DIADOC
- Enrollment
- 70
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Female breast cancer patients, treated with Myocet and cyclophosphamide containing chemotherapy;
- •2\. Life expectancy \>\=12 weeks;
Exclusion Criteria
- •1\. Allopecia prior to start of the study;
- •2\. Simultaneously or shortly after study start: planned skull irradiation (if allopecia is expected);
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Muticentre study to investigate the efficacy of scalp cooling for the prevention of Myocet/cyclofosfamide-induced alopecia in patients with metastatic breast cancer. MyCap studyhaaruitval t.g.v. chemotherapiealopeciahair lossNL-OMON35380Stichting DIADOC70
Completed
Not Applicable
A multi centre study to determine the efficacy and patient acceptability of scalp cooling in the prevention of docetaxel-induced hair loss.Hair lossNL-OMON26657eids Universitair Medisch Centrum in Leiden260
Active, not recruiting
Not Applicable
A study conducted at several study sites with a human growth hormone in a liquid form and a concentration of 3.3. mg/mL that is produced by using genetic engineering techniques, to find out more about how efficacious it works and how safe its use is in pre-pubertal children of small stature who’s bodies do not produce sufficient amounts of own growth hormone.Small stature secondary to growth hormone insufficiency deficiencyTherapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2015-002802-34-Outside-EU/EEASandoz SAS100
Active, not recruiting
Not Applicable
A Multicenter Study Evaluating the Efficacy and Safety of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Headache Prophylaxis in Migraine Patients with 15 or More Headache Days per 4-Week Period in a 24-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase Followed by a 32-Week Open-Label Extension PhaseEUCTR2005-004637-17-DEALLERGAN LTD650
Active, not recruiting
Phase 1
A Multicenter Study Evaluating the Efficacy and Safety of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Headache Prophylaxis in Migraine Patients with 15 or More Headache Days per 4-Week Period in a 24-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase Followed by a 32-Week Open-Label Extension PhaseEUCTR2005-004637-17-GBALLERGAN LTD650